LINC02183: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02183

NCBI ID: G105371273

LINC02183

Other Name(s): long intergenic non-protein coding RNA 2183 | Long intergenic non-protein coding RNA 2183

LINC02183: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC02183 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is located on chromosome 6p21.3 and has a length of approximately 230 nucleotides. LINC02183 is expressed in a variety of tissues and cell types, including brain, heart, and liver. It has been shown to play a role in several cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

LINC02183 has been identified as a potential drug target due to its unique structure and expression pattern. It is a small RNA molecule that can interact with various protein molecules, including nuclear factor of activated T cells (NFAT) and transforming growth factor beta (TGF- ??). LINC02183 has been shown to regulate the activity of NFAT and NF-kappa, which are known to play important roles in cellular processes such as cell adhesion, migration, and transformation.

In addition, LINC02183 has been shown to interact with the protein encoded by the gene KLF1. KLF1 is a key regulator of gene expression and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and translation. LINC02183 has been shown to interact with KLF1 and regulate its activity, which may suggest a potential role for LINC02183 as a drug target.

Biomarker Potential

LINC02183 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. It has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancer. LINC02183 has also been It has also been shown to be expressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to be expressed in cardiovascular diseases, including heart failure and hypertension.

Expression Analysis

To further investigate the potential role of LINC02183 as a drug target, researchers have used RNA sequencing (RNA-seq) to analyze its expression in various tissues and cell types. RNA-seq is a high-throughput sequencing technology that allows researchers to identify and quantify the expression of specific genes in a variety of tissues and cell types.

Studies have shown that LINC02183 is expressed in a variety of tissues and cell types, including brain, heart, and liver. It has been shown to be expressed in brain and heart tissue and has been shown to interact with protein molecules involved in cellular processes such as cell adhesion, migration, and transcription.

Functional Assays

To further investigate the potential role of LINC02183 as a drug target, researchers have used a variety of functional assays to study its interactions with protein molecules. These assays include cell-based assays, such as cell-attachment assays and multi-omics assays, as well as biochemical assays, such as protein-protein interaction (PPI) assays and RNA-protein interaction (RNA-PPI) assays.

Research has shown that LINC02183 can interact with a variety of protein molecules, including NFAT, NF-kappa, and KLF1. These interactions have been shown to play important roles in cellular processes such as

Protein Name: Long Intergenic Non-protein Coding RNA 2183

The "LINC02183 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02183 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets